Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fennec Pharmaceuticals (FENC) Operating Margin (2020 - 2025)

Fennec Pharmaceuticals' Operating Margin history spans 6 years, with the latest figure at 16.06% for Q4 2025.

  • For the quarter ending Q4 2025, Operating Margin rose 2785.0% year-over-year to 16.06%, compared with a TTM value of 3.4% through Dec 2025, down 880.0%, and an annual FY2025 reading of 3.39%, down 880.0% over the prior year.
  • Operating Margin for Q4 2025 was 16.06% at Fennec Pharmaceuticals, up from 1.52% in the prior quarter.
  • The five-year high for Operating Margin was 43555.56% in Q2 2021, with the low at 314.25% in Q1 2023.
  • Average Operating Margin over 5 years is 4041.11%, with a median of 5.37% recorded in 2025.
  • Year-over-year, Operating Margin plummeted -3476784bps in 2022 and then soared 36841bps in 2024.
  • Tracing FENC's Operating Margin over 5 years: stood at 7587.27% in 2021, then tumbled by -91bps to 671.23% in 2022, then crashed by -103bps to 18.67% in 2023, then soared by 37bps to 11.79% in 2024, then surged by 236bps to 16.06% in 2025.
  • Per Business Quant, the three most recent readings for FENC's Operating Margin are 16.06% (Q4 2025), 1.52% (Q3 2025), and 28.31% (Q2 2025).